综上所述，近年来便秘治疗药物的开发和应用呈现以下特点：在疗效方面趋向于更有效、更安全、选择性更强；在组份上则趋于应用更安全的高纯度天然成份或高科技的化学合成物；在相关的药物作用机制和应用的安全性研究方面也更加全面充分。

参考文献

中华医学会外科学分会肛肠外科组.便秘诊治暂行标准.Natl Med J China. 2000 ;80 (7): 491-492.

刘世信等.天津市区人群便秘患病率流行病学研究.中国实用外科杂志.1994;14(9): 533-535.

Stewart WF,et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features.Am J Gastroenterol 1999 ;94(12): 3530-40.

高芳坤等. 北京城乡几种常见老年病流行病学调查. 中华流行病学杂志 1998; 19(3): 159-161.

柯美云等.胃肠通过时间测定.周吕、柯美云,主编.胃肠动力学:基础和临床.北京:科学出版社,1999;429-437.

潘国宗等.肠易激综合征症状学诊断标准的研究. 中华内科杂志 1999; 38(2): 81-84.

Talley NJ,et al. 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.Aliment Pharmacol Ther. 1992 ;6(3):273-89.

Reeves JJ,et al. Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus. Br J Pharmacol 1991 ; 103(1):1067-72.

Nagakura Y,et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res 1999 May;39(5):375-82.

FDA.www.fda.gov/bbs.

Bouras,et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44(5):682-6

Buchheit KH,et al.The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site.J Med Chem. 1995 23;38(13):2326-30.

Buchheit KH,et al.The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J Med Chem. 1995 23;38(13):2331-8.

Drici MD,et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999 ; 34(1):82-8.

Appel S, et al. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J Clin Pharmacol 1997 ; 37(3):229-37.

Appel S,et al. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor     agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997 ; 62(5):546-55.

Farthing MJ et al. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Best Pract Res Clin Gastroenterol 1999; 13(3):461-71.

Prather CM,et al.Tegaserod accelerates orocecal transit in patients with constipation -predominant irritable bowel syndrome. Gastroenterology 2000 ; 118(3):463-8.

E Corazziari. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000 ; 46(4):522-6.

Yuan CS, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000 Jan; 283(3):367-72.

Leng-Peschlow E,et al.Chronic sennoside treatment dose not cause habituation and secondary hyperaldosteronism in rats.Pharmacology 1993 ;47(suppl.1):162-171.

Siegers CP,et al.Anthranoid laxative abuse a risk for colorectal cancer? Gut 1993;34:1099-1101.

Kieman JA,et al.Sennosides do not kill myenteric neurons in the colon of the rat or mouse. Neuroscience 1989;30:837-842.

来源：四川恒泰医药有限公司